IGC Pharma (IGC) Stock Statistics & Valuation Metrics

IGC Pharma has a market cap or net worth of $30.92M. The enterprise value is $26.89M.

IGC Pharma has 83,891,590 shares outstanding. The number of shares has decreased by -2.65% in one year.

IGC Pharma’s return on equity (ROE) is -1.12 and return on invested capital (ROIC) is -113.09%.

The current PE Ratio of {name} is {pe}. {name}’s PEG ratio is {priceToEarningsGrowthRatio}.

In the last 12 months, IGC Pharma had revenue of 1.27M and earned -7.12M in profits. Earnings per share was -0.09.

In the last 12 months, operating cash flow was -4.79M and capital expenditures -260.00K, giving a free cash flow of -5.05M billion.

IGC Pharma pays an annual dividend of ―, resulting in a dividend yield of ―

IGC Pharma upcoming earnings date is Aug 6, 2025, TBA (Confirmed).

IGC Pharma as a current ratio of 1.28, with Debt / Equity ratio of 3.76%

In the past 12 months, IGC Pharma has paid 0.00 in taxes.

IGC Pharma EV to EBITDA ratio is -3.17, with an EV/FCF ratio of -4.10.

IGC Pharma has $405.00K in cash and marketable securities with $238.00K in debt, giving a net cash position of -$167.00K billion.

Gross margin is 48.70%, with operating margin of -585.84%, and net profit margin of -560.27%.

The average price target for IGC Pharma is $4.25, which is 11.43% higher than the current price. The consensus rating is Moderate Buy